---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004474"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-07-15T23:59:59+00:00"
generated_at: "2026-05-18T06:35:07.099189+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptose receives $2M advance from Hanmi under $8.5M loan facility for tuspetinib AML trial

## Summary
- Second advance brings total drawn to $4.5M under the $8.5M loan agreement with Hanmi.
- Funds directed to ongoing TUSCANY Phase 1/2 study of tuspetinib triplet therapy in newly diagnosed AML.
- Tuspetinib combination with venetoclax/azacitidine showed safety and MRD negativity in early data.
- Loan facility announced June 20, 2025; proceeds extend Aptose's cash runway for clinical development.

## SEC filing metadata
- accession: 0001171843-25-004474
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-07-15T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325004474/0001171843-25-004474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325004474/f8k_071525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004474
- JSON: https://secwatch.observer/filing/0001171843-25-004474.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004474.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.